This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CP-868,596

Pfizer Inc.

Drug Names(s): CP-868596

Description: CP-868,596 is a platelet derived growth factor receptor inhibitor (PDGFR).

Deal Structure: Pfizer and OSI entered into a Collaborative Research Agreement effective April 1, 1986. On April 1, 2001, the funded phase of thecollaborative research agreement expired and was not renewed. Following theexpiration of the collaborative research agreement, Pfizer is continuing todevelop certain specified drug candidates which emanated from the collaborativeresearch agreement. CP-868,596 was jointly discovered as result of the partnership; OSI will receive royalties from Pfizer if it is successful in commercializing the drug.

On March 1, 2010, Astellas Pharma announced they will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.

On May 16, 2010, Astellas Pharma and OSI Pharmaceuticals announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI. Under the terms of the merger agreement,...See full deal structure in Biomedtracker

Partners: Astellas Pharma, Inc.


CP-868,596 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug